Answers are grounded in this paper and cite their sources.
Tyrosine phosphorylation (pTyr) plays critical roles in diverse physiological and pathological processes. Mass spectrometry (MS)-based strategies have been developed for mapping pTyr proteome. Nonetheless, ultradeep characterization of pTyr signaling is still hindered by inherently low abundance and highly dynamic range. Here, we designed a sensitive and cost-efficient workflow combining Src homology 2 (SH2) superbinder-based enrichment with data independent acquisition (DIA)-based MS analysis for tyrosine phosphoproteomics. By applying the hybrid DIA (hybDIA) search strategy, this approach identified over 7000 high-confidence pTyr sites, achieving the deepest coverage of the tyrosine phosphoproteome in a single measurement reported thus far. Moreover, this approach showed superior performance on detection sensitivity, data completeness, quantitative robustness, and accuracy. Applied to gefitinib resistance in non-small cell lung cancers (NSCLCs), multiple canonical resistance pathways, including phosphatidylinositol 3-kinase/protein kinase B (PI3K-AKT), epidermal growth factor (EGF) receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance, and erythroblastic leukemia viral oncogene B (ERBB) pathways, were significantly enriched, confirming the reliability and applicability of our analytical workflow. In addition, glycolysis/gluconeogenesis and neurotrophin signaling pathways showed high potential to participate in gefitinib resistance. In light of these findings, drug combination experiments further demonstrated that inhibitors of acetyl-CoA carboxylase (ACC) or tropomyosin receptor kinase (TRK) significantly enhanced the therapeutic efficacy of gefitinib. Phosphorylation at nuclear envelope membrane protein 1 (NEMP1) Ser368, ribosomal protein S6 kinase b1 (RPS6KB1) Ser441/Thr444, and cortactin (CTTN) Tyr154 showed potentially important roles in gefitinib resistance. Functional rescue assay of NEMP1 Ser368 and RPS6KB1 Ser441/Thr444 further demonstrated that phosphorylation-defective mutant, compared to the phosphomimetic mutant, significantly enhanced the sensitivity of resistant cell to gefitinib. Collectively, this study provides a powerful tool for Tyr phosphoproteomics, facilitating mechanistic insights into the EGFR-TKI resistance in NSCLC.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: